Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Quidel's MDx for Bordetella Pertussis

NEW YORK (GenomeWeb) – Quidel said after the close of the market on Wednesday that the US Food and Drug Administration has cleared the company's AmpliVue Bordetella Assay. 

The assay detects Bordetella pertussis nucleic acids isolated from nasopharyngeal swab specimens from patients suspected of having a respiratory tract infection due to the bacteria, which causes whooping cough. 

Quidel's test is a self-contained handheld molecular diagnostic that requires no upfront DNA extraction and can generate results in about 75 minutes. The AmpliVue Bordetella Assay is CLIA-classified as moderately complex. It is the fifth assay in the AmpliVue format, the San Diego-based company said. In July the FDA cleared the AmpliVue GAS Assay for detection of Group A Streptococcus. In late 2013, it cleared the AmpliVue Group B Strep Assay, and in 2012, it cleared the AmpliVue C. difficile assay.

The AmpliVue technology was developed by BioHelix which Quidel acquired last year. Even before the acquisition, though, Quidel had been using the technology, dubbed helicase-dependent amplification (HAD), under a collaborative R&D agreement forged by the two firms in 2009. 

"We've shown that we can harness our proprietary HAD technology to develop fast, accurate, molecular diagnostics assays with a menu that matters to our customers," Quidel President and CEO Douglas Bryant said in a statement. "Longer term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.